Shuhei Okazaki1, Manabu Sakaguchi2, Kaori Miwa2, Shigetaka Furukado2, Hiroshi Yamagami2, Yoshiki Yagita2, Hideki Mochizuki2, Kazuo Kitagawa1. 1. From the Department of Neurology, Osaka University Graduate School of Medicine, Osaka, Japan (S.O., M.S., K.M., S.F., Y.Y., H.M.); Department of Neurology, National Cerebral and Cardiovascular Center, Osaka, Japan (H.Y.); and Department of Neurology, Tokyo Women's Medical University, Tokyo, Japan (K.K.). s-okazaki@umin.ac.jp kkitagawa@nij.twmu.ac.jp. 2. From the Department of Neurology, Osaka University Graduate School of Medicine, Osaka, Japan (S.O., M.S., K.M., S.F., Y.Y., H.M.); Department of Neurology, National Cerebral and Cardiovascular Center, Osaka, Japan (H.Y.); and Department of Neurology, Tokyo Women's Medical University, Tokyo, Japan (K.K.).
Abstract
BACKGROUND AND PURPOSE: Limited information is available on the long-term effects of interleukin-6 (IL-6) on systemic atherosclerosis. The purpose of the present study was to clarify the relationship between chronic elevation of IL-6 and the long-term progression of carotid atherosclerosis. METHODS: We prospectively evaluated 210 patients with ≥1 vascular risk factors for 9.0±1.0 years. Carotid mean-maximal intima-media thickness (mmIMT), the serum high-sensitivity C-reactive protein (hs-CRP) level, and the serum IL-6 level were measured at baseline and every 3 years. The associations between the progression of mmIMT and the long-term average levels of hs-CRP and IL-6 were analyzed. RESULTS: Carotid mmIMT increased throughout the study period (0.031±0.026 mm/y). Baseline mmIMT was significantly associated with baseline hs-CRP (P=0.002) and baseline IL-6 (P<0.001) levels. Progression of mmIMT was positively correlated with average hs-CRP (P=0.001) and average IL-6 (P<0.001) levels. When adjusted for age, sex, traditional risk factors, and baseline mmIMT, mmIMT progression remained significantly associated only with the average IL-6 level (standardized β=0.17; P=0.02), but not with the average hs-CRP level (standardized β=0.10; P=0.18). CONCLUSIONS: Chronic elevation of serum IL-6 was associated with the progression of atherosclerosis in patients with vascular risk factors. IL-6 could be used as a quantitative marker and a potential therapeutic target for accelerated atherosclerosis.
BACKGROUND AND PURPOSE: Limited information is available on the long-term effects of interleukin-6 (IL-6) on systemic atherosclerosis. The purpose of the present study was to clarify the relationship between chronic elevation of IL-6 and the long-term progression of carotid atherosclerosis. METHODS: We prospectively evaluated 210 patients with ≥1 vascular risk factors for 9.0±1.0 years. Carotid mean-maximal intima-media thickness (mmIMT), the serum high-sensitivity C-reactive protein (hs-CRP) level, and the serum IL-6 level were measured at baseline and every 3 years. The associations between the progression of mmIMT and the long-term average levels of hs-CRP and IL-6 were analyzed. RESULTS: Carotid mmIMT increased throughout the study period (0.031±0.026 mm/y). Baseline mmIMT was significantly associated with baseline hs-CRP (P=0.002) and baseline IL-6 (P<0.001) levels. Progression of mmIMT was positively correlated with average hs-CRP (P=0.001) and average IL-6 (P<0.001) levels. When adjusted for age, sex, traditional risk factors, and baseline mmIMT, mmIMT progression remained significantly associated only with the average IL-6 level (standardized β=0.17; P=0.02), but not with the average hs-CRP level (standardized β=0.10; P=0.18). CONCLUSIONS: Chronic elevation of serum IL-6 was associated with the progression of atherosclerosis in patients with vascular risk factors. IL-6 could be used as a quantitative marker and a potential therapeutic target for accelerated atherosclerosis.
Authors: Britta A Larsen; Gail A Laughlin; Kevin Cummins; Elizabeth Barrett-Connor; Christina L Wassel Journal: Atherosclerosis Date: 2017-07-22 Impact factor: 5.162
Authors: Denise C Hsu; Yi Fei Ma; Sophia Hur; Danny Li; Adam Rupert; Rebecca Scherzer; S C Kalapus; Steven Deeks; Irini Sereti; Priscilla Y Hsue Journal: AIDS Date: 2016-08-24 Impact factor: 4.177
Authors: Joseph Kamtchum-Tatuene; Luca Saba; Mirjam R Heldner; Michiel H F Poorthuis; Gert J de Borst; Tatjana Rundek; Stavros K Kakkos; Seemant Chaturvedi; Raffi Topakian; Joseph F Polak; Glen C Jickling Journal: Circ Res Date: 2022-06-17 Impact factor: 23.213